Certa Therapeutics

About

Certa Therapeutics discovers and develops receptor-blocking drugs for kidney, skin, and organ fibrosis and uses diagnostic and genetic testing to select patients for precision antifibrotic therapies.

Mission

Certa Therapeutics focuses on discovering and developing novel drugs that block a receptor implicated in fibrosis of the kidney, skin and other organs. The company applies diagnostic testing and genetic information to identify patients most likely to benefit from its precision therapies. A key clinical focus is treating kidney fibrosis to reduce progression to dialysis or transplantation, addressing a currently unmet medical need. Certa’s technologies are described in the article as potentially worth up to US$5 billion annually if successful. The company has received a significant capital injection to support late-stage development and commercialization efforts. The article is dated June 4, 2018 and references activity in Melbourne, Australia.

Quick Facts